U.S. Markets close in 4 hrs 56 mins

Did You Miss Pieris Pharmaceuticals's (NASDAQ:PIRS) 56% Share Price Gain?

Simply Wall St

By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, the Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) share price is up 56% in the last three years, clearly besting than the market return of around 41% (not including dividends).

See our latest analysis for Pieris Pharmaceuticals

Because Pieris Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last 3 years Pieris Pharmaceuticals saw its revenue grow at 81% per year. That's much better than most loss-making companies. While the compound gain of 16% per year over three years is pretty good, you might argue it doesn't fully reflect the strong revenue growth. If that's the case, now might be the time to take a close look at Pieris Pharmaceuticals. A window of opportunity may reveal itself with time, if the business can trend to profitability.

The chart below shows how revenue and earnings have changed with time, (if you click on the chart you can see the actual values).

NasdaqCM:PIRS Income Statement, April 28th 2019

If you are thinking of buying or selling Pieris Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Pieris Pharmaceuticals shareholders are down 50% for the year, but the broader market is up 11%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Fortunately the longer term story is brighter, with total returns averaging about 16% per year over three years. The recent sell-off could be an opportunity if the business remains sound, so it may be worth checking the fundamental data for signs of a long-term growth trend. If you would like to research Pieris Pharmaceuticals in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.